Monosodium Glutamate (MSG) Renders Alkalining Properties and Its Urinary Metabolic Markers of MSG Consumption in Rats

Kanokwan Nahok 1,2, Jia V. Li 3,4, Jutarop Phetcharaburanin 1, Hasina Abdul 3, Chaisiri Wongkham 1, Raynoo Thanan 1, Atit Silsirivanit 1, Sirirat Anutrakulchai 2,5, Carlo Selmi 6,7,* and Ubon Cha’on 1,2,*

1 Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand; Kanokwan.nahok@gmail.com (K.N.); jutarop@kku.ac.th (J.P.); chaisiri@kku.ac.th (C.W.);
raynoo@kku.ac.th (R.T.); atitsil@kku.ac.th (A.S.)
2 Chronic Kidney Disease prevention in the Northeast Thailand (CKDNET), Khon Kaen University, Khon Kaen 4002, Thailand; sirirat_a@kku.ac.th
3 Department of Metabolism, Digestive Disease and Reproduction, Faculty of Medicine, Imperial College London, South Kensington, London SW7 2AZ, UK; jia.li@imperial.ac.uk (J.V.L.);
hasinaabdul@hotmail.co.uk (H.A.)
4 Centre for Digestive and Gut Health, Institute of Global Health Innovation, Imperial College London, London SW7 2AZ, UK
5 Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
6 Rheumatology and Clinical Immunology, IRCCS Humanitas Clinical and Research Center, 20089 Milan, Italy
7 BIOMETRA Department, University of Milan, 20089 Milan, Italy
* Correspondence: carlo.selmi@humanitas.it (C.S.); ubocha@kku.ac.th (U.C.)

Received: 23 August 2019; Accepted: 26 September 2019; Published: 27 September 2019

Abstract: Monosodium glutamate (MSG) is widely used as a flavor enhancer and its effects on human health are still debated. We aimed to investigate whether MSG can act as an alkalinizing agent in murine models and if its metabolites are biomarkers of MSG consumption. For this purpose, adult male Wistar rats were given water added with 1 g% MSG or three types of control water, including sodium chloride (NaCl) and sodium bicarbonate (NaHCO₃). At 14 days, urinary pH, electrolytes, urinary metabolites and ion-exchanger gene expression were determined. The results revealed that MSG-treated rats had significantly more alkaline urine and higher levels of urinary sodium and bicarbonate similar to NaHCO₃ controls. These changes correlated with a lower expression of ion-exchanger genes, namely, CAII, NBC1, and AE1, which are involved in bicarbonate kidney reabsorption. The urinary metabolic profiles also revealed similar patterns for the MSG and NaHCO₃ groups. In conclusion, MSG exhibits similar properties to NaHCO₃, an alkalinizing agent, with regard to inducing alkaline urine, reducing bicarbonate kidney reabsorption, and generating a specific urinary metabolic pattern. We believe that these observations will be useful to further study the MSG effects in humans.

Keywords: monosodium glutamate; metabolic profiles; alkaline urine; ion exchangers

1. Introduction

Monosodium glutamate (MSG) is commercially produced as a flavor enhancer in processed foods and home cooking and its use is exponentially increasing worldwide [1]. Although the Food and Drug Administration (FDA) have classified MSG as a safe food ingredient [2], its safety as a food additive is still debated. For example, cross-sectional and longitudinal studies from our group and others have revealed that the consumption of MSG is associated with human metabolic syndrome [3], obesity [4,5], and arterial hypertension [6], although conflicting evidence is also available [7,8].
The metabolic effects of both oral and parenteral MSG seem to be consistent in animal models, with data available on the effects of MSG on the liver [9–11], pancreas [12,13] and kidney [9,14]. MSG causes alkaline urine in rats following long-term consumption [14]. Urine alkalinization using available alkalinizing agents such as potassium citrate (K citrate) [15,16] and sodium bicarbonate (NaHCO$_3$) [17,18] is a common treatment for several medical conditions, with the latter used for treating patients who have acute metabolic acidosis or renal proximal tubular acidosis [19]. Of importance, potassium citrate has limitations in patients with hyperkalemia [20–22] and in long-term supplementation, and NaHCO$_3$ may lead to adverse events such as systemic alkalosis [19].

Since alkalinizing agents should be used with caution in specific subjects, it is very important to identify whether MSG is also able to alkalinize urine, even though our previous observations revealed that a 9-month exposure to MSG did not affect the blood pH [14]. We herein report that oral MSG (resembling human intake) can alkalinize urine within two weeks and our $^1$H-NMR-based metabolomics approach revealed that MSG induced urinary metabolic profiles were similar to those of NaHCO$_3$, an alkalinizing agent. We ultimately submit that urinary metabolites may be useful for monitoring dietary consumption, and thus predict MSG effects in human.

2. Materials and Methods

2.1. Chemicals and Animals

We used 99% pure food-grade MSG (Ajinomoto, Japan), NaCl (RCI Labscan, Thailand), NaHCO$_3$ (BDH, Visalia, CA, USA) and 40 6-week old male Wistar rats (approximately 200 g) obtained from the National Laboratory Animal Center (Salaya, Mahidol University, Bangkok, Thailand). Animals were housed for 2 weeks in the Northeast Laboratory Animal Center and maintained under standard conditions (temperature: 23 ± 2 °C, humidity (RH): 30–60%, brightness: 350–400 Lux and 12 h/12 h dark/light cycle) with standard rat chow pellets (Perfect Companion Group, Bangkok, Thailand). All experiments were performed in accordance with the guidelines of KKU animal ethics (AEKKU-NELAC 5/2558).

2.2. Experimental Design

Rats were assigned into 4 groups, (1) receiving drinking water, (2) receiving water with 1 g% MSG added, (3) receiving water with 0.34 g% NaCl added, which equivalent to the sodium in group 2, and (4) receiving water with 2.4 g% NaHCO$_3$ as a positive control for the alkalinizing agent treated group (Figure 1). Animals were allowed to access water and food ad libitum and daily water intake was recorded weekly. Food intake (g/day) was measured every 2 weeks. Rats were housed in individual stainless steel metabolic cages for urine sample collection. Urinary samples (24-h urine) were collected one day before (D1) and 14 days after the experiment (D14) and kept at −80 °C until analyzed. At the end of the experiment (D14), all animals were sacrificed using carbon dioxide after 12-h fasting. Kidneys were dissected, washed with normal saline, and divided into cortex and medulla layer, then transferred to cryotubes with TRizol$^{\circledR}$ Reagent (Invitrogen, Waltham, MA, USA), dipped in liquid nitrogen and stored at −80 °C for gene expression analysis.

2.3. Urine Analysis

The 24 h urine was thawed at room temperature and analyzed for urine pH and urine electrolyte (sodium, potassium, chloride and bicarbonate). All samples were analyzed at the laboratory services in Srinagarind Hospital, Khon Kaen University and using automatic machine under standard protocol.
2.4. Sample Preparation for 1H-NMR Spectroscopic Analysis

Urine samples were thawed at room temperature and centrifuged at 18,000×g, 4 °C, for 10 min. Then 100 µL of the urine supernatant was transferred to a new tube and mixed with 300 µL of deuterium oxide (D2O) (Sigma Aldrich, Gillingham Dorset, UK) and 250 µL of 0.2 M sodium phosphate buffer containing 0.1% sodium trimethylsilyl-[2,2,3,3-2H4]-propionate (TSP), 100% D2O and 3 mM sodium azide. The sample was vortexed briefly, and then 600 µL of the mixture was transferred to NMR glass tubes (Wilmad-labglass, Vineland, NJ, USA) with an outer diameter of 5 mm pending NMR analysis.

2.5. 1H-Nuclear Magnetic Resonance Spectroscopic Analysis of Urine

Urinary samples were analyzed using a Bruker 600 MHz spectrometer (Bruker Avance III, Bruker Biospin, Rheinstetten, Germany) at a 1H frequency of 600.13 MHz with a temperature of 300 K. A standard one-dimensional (1-D) NMR pulse sequence (recycle delay [RD]-90°-t1-90°-tm-90°-acquire free induction decay) was used. t1 was fixed to 3 µs. The suppression of the water peak was achieved by selective irradiation during recycle delay of 2 s and mixing time (tm) of 100 ms. The 90 degree-pulse was adjusted to approximately 10 µs. A total of 128 scans were recorded into 64 K data points with a spectral width of 20 ppm [23].

2.6. Data Pre-Processing and Multivariate Statistical Analysis

The urinary spectra were calibrated to the TSP peak (δ1H 0.00), phased and baseline corrected using TopSpin 3.0 (Bruker, Rheinstetten, Germany). The pre-processed spectra were imported into MATLAB software (MathWorks, R2014a, Natrick, MA, USA) and digitized with a resolution of 0.0005 ppm. Spectral regions containing the TSP peak (δ1H –1.00–0.005), water (δ1H 4.70–4.90) and urea (δ1H 5.71–6.00) were removed. Normalization using the probabilistic quotient method [24] and peak alignment using recursive segment-wise peak alignment (RSPA) [25] were applied to the remaining spectral data. Unsupervised principal component analysis (PCA) with unit variance (UV) scaling method was initially performed in order to identify any obvious clustering or outliers to unassigned treatment groups. The orthogonal-signal correction-projection to latent structures-discriminant analysis (O-PLS-DA) was then used to investigate the metabolic difference between the control and MSG groups. The O-PLS-DA models are evaluated by the R²X and Q²Y values, representing the fitness and predictivity of the model, respectively. A two-tailed heteroscedastic t-test with Benjamini-Hochberg correction was also used to determine the statistical significance of differences between the groups.
version 3.6, Edmonton, AB, Canada) [26,27] and in-house chemical shift databases were used for metabolite identification.

2.7. Gene Expression Analysis

Total RNAs were extracted from cortex and medulla layers of kidney using TRIzol® reagent method. Tissues weighing about 50–100 mg were preserved in TRIzol® and incubated at room temperature (RT) for 3 min, 200 µL of chloroform was added the mixture was shaken vigorously and incubated at RT for 3 min. The reaction was then centrifuged at 12,000×g for 15 min at 4 °C. The upper aqueous phase (60%) was transferred to a new 1.5 mL sterile tube, 500 µL of isopropanol was added, mixed well, and then incubated at RT for 10 min and centrifuged at 12,000×g for 10 min at 4 °C. The supernatant was discarded while the pellet was washed by 70% ethanol and centrifuged at 7500×g for 5 min at 4 °C (twice). The pellet was air dried at RT, re-suspended in 30–50 µL of DEPC water and then the pellet was dissolved by keeping it at 55 °C for 15 min. Total RNA were stored at −80 °C until used.

RNA concentration was measured with OD at 260 nm and reverse-transcribed to complementary DNA (cDNA) using the high capacity reverse transcription Kit (Applied Biosystem, Foster, CA, USA). Obtained cDNA was diluted to 20 ng/µL and stored at −20 °C until used. Gene expression analysis was determined by real-time PCR, using beta-actin (ACTB) as the internal control for normalization [28], in LightCycler® 480 real-time PCR system (Roche Applied Science, Mannheim, Germany). Each PCR condition containing 2.5 µM of primers (forward and reverse primers), cDNA 50 ng/µL, and 2X LightCycler® 480 SYBR green I master mix. The amplification was initiated by pre-incubation at 95 °C for 10 min, followed by 40 cycles at 94 °C for 30 s, 60 °C for 30 s, 72 °C for 1 min, and 79 °C for 0.1 s. Each sample was prepared in duplicate sample and the crossing point (Cp) cycle was calculated and presented as mean ± SEM values. The gene expression levels were determined and the $2^{-\Delta\text{Cp}}$ value; $\Delta\text{Cp} = \text{Cp}_{\text{target}} - \text{Cp}_{\text{actin}}$ was calculated. Primers for all genes were designed using NCBI with a least one exon-exon junction in the target (Table 1).

2.8. Statistical Analysis

The statistical analysis of the urinary analysis and gene expression were reported as mean ± SEM per group of animals and the differences between groups was compared for statistical significance by Student’s t-test. Moreover, all comparisons of gene expression with $p$-values < 0.05 were considered as statistically significant.
Table 1. Oligonucleotide primers used for gene expression analysis.

| Group                | Gene          | Primer Direction   | Oligonucleotide Sequence          | Product Size (bp) |
|----------------------|---------------|--------------------|----------------------------------|------------------|
| Internal Control     | Beta-actin    | Forward            | ACAACCTTTCTGCGACTCTCT           | 197              |
|                      |               | Reverse            | ACCCATACCCCATATACAC              |                  |
| AE1                  |               | Forward            | TCCCGCTACACTCAGGAGAT            | 118              |
|                      |               | Reverse            | CAGGGGCAATGCTCTGTTGTC           |                  |
| CAII                 |               | Forward            | TGCTGGAATGTTGAGCCTGG            | 101              |
|                      |               | Reverse            | CTCCTCCGAAATTGAGT              |                  |
| Na⁺/K⁺ ATPase        |               | Forward            | CAGCAGGACTCGATGAGTT              | 189              |
|                      |               | Reverse            | GGCAGGAGCAGCATGAGATA            |                  |
| H⁺/K⁺ ATPase         |               | Forward            | CCCCTGAGTACCTGAGT              | 168              |
|                      |               | Reverse            | CCACAACCACAGAATGAGT            |                  |
| Ion-Exchanger        | AE1           | Forward            | TCCCGCTACACTCAGGAGAT            | 118              |
|                      |               | Reverse            | CAGGGGCAATGCTCTGTTGTC           |                  |
|                      | CAII          | Forward            | TGCTGGAATGTTGAGCCTGG            | 101              |
|                      |               | Reverse            | CTCCTCCGAAATTGAGT              |                  |
|                      | Na⁺/K⁺ ATPase | Forward            | CAGCAGGACTCGATGAGTT              | 189              |
|                      |               | Reverse            | GGCAGGAGCAGCATGAGATA            |                  |
|                      | H⁺/K⁺ ATPase  | Forward            | CCCCTGAGTACCTGAGT              | 168              |
|                      |               | Reverse            | CCACAACCACAGAATGAGT            |                  |
| CA IV                |               | Forward            | GTCTATGCCCCTCAAGACCA            | 114              |
|                      |               | Reverse            | TTGGGCTCTTGGCTTGAAT            |                  |
| NBC1                 |               | Forward            | GCTATCCGGCTTGGTFTAGT            | 153              |
|                      |               | Reverse            | GAAGGCGACACACACATGA            |                  |
| NHE3                 |               | Forward            | ACTGCTTAATGAGCCGCTG            | 160              |
|                      |               | Reverse            | GAAGGCGAAGATAGCACCA            |                  |
| Rhbg                 |               | Forward            | TGCCGCTACAAACCACGAAA          | 96               |
|                      |               | Reverse            | TGGAACTTTGGTGAGCAGGA            |                  |
| Rhcg                 |               | Forward            | CTCTTCGCGCTTGTGTC                  | 200              |
|                      |               | Reverse            | CCTCAAGCGCTGAACACCA            |                  |
| Pendrin              |               | Forward            | AGAACCAAGCCAAATCCAGG            | 83               |
|                      |               | Reverse            | CAAGCTACAGCTGGCTTA            |                  |
| H⁺-ATPase            |               | Forward            | TGGCCCATGTTGAGCGGGGACA         | 147              |
|                      |               | Reverse            | TGCAGAGAGCTGAGGAGGCAA           |                  |
| Glutamate and        | XC-sys        | Forward            | GCATGCTCCTTTCAAGGAGC            | 150              |
| Glutamine Metabolism |               | Reverse            | AAGAGGTAATAGCCCGGGAAC           |                  |
|                      | EAAC1         | Forward            | AAACCCAGGTGCTCAGTCT            | 127              |
|                      |               | Reverse            | ACCGGGCTTGTGGAGGAATC           |                  |
|                      | Glutaminase   | Forward            | TGCCATGAGTGTTGAGCTCT          | 199              |
|                      |               | Reverse            | TACCAGCAAAACAGGAGGTT           |                  |
|                      | SNAT3         | Forward            | GGAAAGGGATGTTGAGAGT            | 83               |
|                      |               | Reverse            | CTGAACACCCCCAGACCC            |                  |
|                      | PEPCK         | Forward            | TGCCATGCTGCTATGACCC          | 89               |
|                      |               | Reverse            | TTGGATATGCTACGGGCTGTA         |                  |
| TCA Cycle            | Citrate synthase | Forward            | TGCTACAGAAGACACTAGTCCAC        | 243              |
|                      |               | Reverse            | ATCTGACAGCTTCTGAGCCGA          |                  |
|                      | Aconitase     | Forward            | CCTGTACCTGAACCTGTCG            | 223              |
|                      |               | Reverse            | TGTAGTCAGAGGGCTAGCA           |                  |
|                      | IDH           | Forward            | TGCAAAATATCCCTCCCGCT          | 144              |
|                      |               | Reverse            | GCAATCCCTTTGGGAGGAGA            |                  |

Abbreviations: AE1: anion exchanger1, CAII: carbonic anhydrase2, CAIV: carbonic anhydrase4, NBC1: Na⁺/HCO₃⁻ co-transporter1, NHE3: Na⁺/H⁺ exchanger3, Rhbg: Rh family B glycoprotein, Rhcg: Rh family C glycoprotein, XC-sys: Cysteine/glutamate transporter, EAAC1: Excitatory amino acid transporter1, SNAT3: Na⁺-coupled neutral amino acid transporter3, PEPCK: Phosphoenolpyruvate carboxykinase, IDH: Isocitrate dehydrogenase.

3. Results

3.1. MSG Exhibits Urine Chemistries Similar to Alkaline Loading

After two weeks, urine analyses indicated that the MSG and NaHCO₃ treatment groups had significantly higher urine pH compared to controls (pH = 7.82, pH = 9.13, and pH = 6.86, respectively;
*** p < 0.001 for both groups vs. controls), whereas no significant difference in urinary pH was observed between NaCl-treated rats (pH = 6.93) and controls (Figure 2A). Urinary Na⁺ was significantly higher in MSG, NaCl, and NaHCO₃-treated rats compared to controls (3.1 ± 0.17, 4.59 ± 0.31, 8.84 ± 1.12, 1.28 ± 0.05 mEq/day, respectively). Urinary K⁺ excretion in MSG group (1.83 ± 0.06 mEq/day) was significantly higher, whereas the NaHCO₃-treated group (1.04 ± 0.12 mEq/day) was the opposite to controls (1.50 ± 0.10 mEq/day). Significantly higher levels of HCO₃⁻ were also revealed in MSG (0.95 ± 0.16 mEq/day) and NaHCO₃-treated rats (1.14 ± 0.20 mEq/day) but not in NaCl-treated rats (0.20 ± 0.06 mEq/day) compared to controls (0.19 ± 0.02 mEq/day). No significant differences in urinary Cl⁻ were observed between MSG (3.70 ± 0.26 mEq/day) and NaCl-treated rats (3.85 ± 0.31 mEq/day), whereas significantly lower levels were found in NaHCO₃-treated rats (1.88 ± 0.20 mEq/day) compared to control rats (4.32 ± 0.28 mEq/day) (Figure 2B).

Figure 2. Urine pH (A) and electrolytes (B) after treatment in male Wistar rats supplemented with 1 g% MSG, 0.34 g% NaCl and 2.4 g% NaHCO₃ (n = 10 per group). Data are shown as mean ± SEM and p-values calculated by Student’s t-test (* p < 0.05, ** p < 0.01, *** p < 0.001).

3.2. MSG Suppresses HCO₃⁻ Reabsorption Similar to Alkaline Loading

We used RT-PCR to analyze the expression of the 11 ion-exchanger genes that contribute to the acid-base regulation in the kidney cortex, including the expression of genes related to glutamine/glutamate metabolism and the TCA cycle (Table 1). Three important ion-exchanger genes involved in HCO₃⁻ reabsorption (CAII, NBC1, and AE1) were suppressed in MSG-treated rats (1.62 ± 0.456, 0.16 ± 0.065, 0.01 ± 0.002, respectively), similar to that of the NaHCO₃ group (1.02 ±
0.125, 0.20 ± 0.034, 0.02 ± 0.001, respectively) when compared to controls (4.30 ± 0.865, 0.57 ± 0.127, 0.10 ± 0.041, respectively) (Figure 3). No significant differences were observed for CAII, NBC1, and AE1 mRNA expression levels in NaCl-treated rats compared to controls. Glutamine/glutamate metabolism and TCA cycle gene expression in kidney were unchanged in MSG, NaCl and NaHCO₃ compared to control groups (data shown in Supplementary Materials).

### 3.3. MSG Shares Common Urinary Metabolic Profile Resembling Alkaline Loading

**Figure 3.** Changes in mRNA expression of ion exchanger genes in cortex layers of rat kidney after 14 days of MSG (n = 10), NaCl (n = 10) and NaHCO₃ (n = 10) supplementation compared to controls (n = 8) (A) CAII, (B) NBC1, (C) AE1. Data are shown as mean ± SEM relative gene expression with beta-actin, * p < 0.05; ** p < 0.01; *** p < 0.001. Abbreviations: CAII: carbonic anhydrase2, NBC1: Na⁺-HCO₃⁻ co-transporter1; AE1: anion exchanger1.

### 3.3. MSG Shares Common Urinary Metabolic Profile Resembling Alkaline Loading

¹H-NMR spectra of 24 h urine samples from control, MSG, NaCl and NaHCO₃-treated groups at day 14 (D14) are plotted in Figure 4. Differences in raw spectra between 4.5 ppm and 5.25 ppm were observed in MSG and NaHCO₃-treated rats compared to NaCl and control rats (Figure 4). Urinary NMR spectral data was analyzed using PCA and the scores plot is shown in Figure 5. No clustering based on the treatment group was observed in the PCA scores plot (Figure 5A). However, the O-PLS-DA cross-validated scores plot shows a clear separation between controls and MSG at D14 (Figure 5B) with a permutation p-value of 0.001, R²X of 44%, and Q²Y of 0.75. Based on PCA and O-PLS-DA, no clustering or separation was observed between controls and the NaCl-treated group (Figure 5C,D). In contrast, clear clustering and complete separation were observed based on PCA and O-PLS-DA, between controls and the NaHCO₃-treated group (Figure 5E,F) with a permutation p value of 0.001, R²X of 47%, and Q²Y of 0.95.
Figure 4. The 600 MHz $^1$H-NMR spectra of urinary samples collected over 24 h at day 14 from (A) control, (B) MSG-fed, (C) NaCl-fed, and (D) NaHCO$_3$–fed rats ($n=10$ per group).

The detected urinary metabolite changes are summarized in Table 2 and changes in the urinary profiles were observed in MSG and NaHCO$_3$-treated rats when compared with control animals. In particular, nine urinary metabolites, including glutamate, citrate, malonate, alpha-ketoglutarate, beta-hydroxyisovalerate, 5-aminovaleate, 5-hydroxymethyl-4-methyluracil, dimethylamine, and methylamine were significantly higher in the MSG treatment group, whereas taurine was significantly higher in control animals. Seven urinary metabolites, including glutamate, citrate, malonate, alpha-ketoglutarate, 5-aminovaleate, beta-hydroxyisovalerate, and taurine found in the MSG group were also observed in the NaHCO$_3$ group. However, three metabolites, i.e., 3-carboxy-2-methyl-3-oxopropanamine, succinate, and choline were significantly higher in the NaHCO$_3$ group compared to controls. The 5-hydroxymethyl-4-methyluracil metabolite was significantly altered in both MSG and NaHCO$_3$, but in opposite ways. The similar effects of MSG and NaHCO$_3$ supplementation on urine pH, urine electrolytes, ion exchanger gene expression and urinary metabolic markers are illustrated in Table 3.
Figure 5. PCA scores plots (left panel) and O-PLS-DA cross-validated scores plots (right panel) of 24-h urine at day 14 (U24 D14). (A,B): control (blue) vs. MSG (red); (C,D): control (blue) vs. NaCl (green); (E,F): control (blue) vs. NaHCO$_3$ (brown) ($n = 10$ per group).
Table 2. Relative changes at 2 weeks of 24 h urine metabolites in control, MSG and NaHCO₃ rats \((n = 10\) per group) using the \(^1\)H-NMR profiles.

| Metabolites                  | Chemical Shift (Multiplicity) | MSG and NaHCO₃ Induced Metabolic Changes Compared to Control | The Acid Dissociation Constant (pKa) |
|------------------------------|-------------------------------|-------------------------------------------------------------|-------------------------------------|
|                              |                               | (−) Control vs. (+) MSG \(R²X = 44\%, Q²Y = 0.73, p = 0.001\) |                                     |
|                              |                               | (−) Control vs. (+) NaHCO₃ \(R²X = 47\%, Q²Y = 0.95, p = 0.001\) |                                     |
| 3-carboxy-2-methyl-3-oxopropanamine | 1.08 (d); 2.49 (m); 3.19(m); 3.56 (m); 3.72 (m) | - (\(0.95\)(\(Δ3.33 \times 10^{-10}\)) |                                     |
| Beta-hydroxyisovalerate       | 1.28 (s)                      | (\(0.77\)(\(Δ6.19 \times 10^{-5}\)) (\(0.89\)(\(Δ1.83 \times 10^{-7}\)) |                                     |
| 5-aminovalerate              | 1.68 (m); 2.21 (t); 3.02 (t)  | (\(0.79\)(\(Δ3.35 \times 10^{-5}\)) (\(0.95\)(\(Δ1.38 \times 10^{-10}\)) |                                     |
| 5-hydroxymethyl-4-methyluracil | 1.98 (s); 4.42 (s)            | (\(0.83\)(\(Δ5.84 \times 10^{-6}\)) (\(-0.84\)(\(Δ4.15 \times 10^{-10}\)) |                                     |
| Glutamate                    | 2.02 (m); 2.34 (m); 3.76 (m)  | (\(0.85\)(\(Δ2.31 \times 10^{-5}\)) (\(0.88\)(\(Δ2.91 \times 10^{-7}\)) | \(pK_{A1} = 2.19, pK_{A2} = 4.25, pK_{A3} = 9.67\) |
| Succinate                    | 2.41 (s)                      | - (\(0.87\)(\(Δ8.10 \times 10^{-7}\)) | \(pK_{A1} = 4.16, pK_{A2} = 5.61\) |
| Alpha-ketoglutarate          | 2.44 (t); 3.01 (t)            | (\(0.75\)(\(Δ1.37 \times 10^{-4}\)) (\(0.89\)(\(Δ1.46 \times 10^{-7}\)) | \(pK_{A1} = 2.47, pK_{A2} = 4.68\) |
| Citrate                      | 2.54 (d); 2.66 (d)            | (\(0.87\)(\(Δ5.10 \times 10^{-7}\)) (\(0.96\)(\(Δ4.63 \times 10^{-11}\)) | \(pK_{A1} = 3.14, pK_{A2} = 4.77, pK_{A3} = 6.39\) |
| Methylamine                  | 2.61 (s)                      | (\(0.52\)(\(Δ0.019\)) - | \(pK_{A1} = 10.63\) |
| Dimethylamine                | 2.77 (s)                      | (\(0.71\)(\(Δ4.76 \times 10^{-4}\)) - | \(pK_{A1} = 2.36, pK_{A2} = 10.21\) |
| Malonate                     | 3.11 (s)                      | (\(0.74\)(\(Δ2.17 \times 10^{-4}\)) (\(0.97\)(\(Δ1.66 \times 10^{-12}\)) | \(pK_{A1} = 2.85, pK_{A2} = 5.70\) |
| Choline                      | 3.21 (s); 3.52 (m); 4.07 (m)  | (\(0.80\)(\(Δ2.70 \times 10^{-5}\)) | \(pK_{A1} = 13.9\) |
| Taurine                      | 3.25 (t); 3.43 (t)            | (\(-0.75\)(\(Δ2.69 \times 10^{-4}\)) (\(-0.80\)(\(Δ2.80 \times 10^{-5}\)) | \(pK_{A1} = 1.15, pK_{A2} = 9.06\) |

\(R²X\) and \(Q²Y\) show the variance explained and predicted by each model while \(p\) values for all models were derived from the permutation test \((n = 1000)\). (\(+)\) indicates a higher correlation, whereas (−) indicates a lower correlation of urinary metabolite after MSG and NaHCO₃ consumption. (*) represents the correlation value and (Δ) represents the \(p\) value of the specific peak. The bolded chemical shift per metabolite was used as the STOCSY driver peak and for deriving the correlation and \(p\)-value. (\(* p < 0.05, ** p < 0.01, *** p < 0.001\)). Abbreviations: s, singlet; d, doublet; t, triplet; m, multiplet, pKa; acid dissociation constant. Note: (−) Control vs. (+) NaCl, \(R²X = 38\%, Q²Y = 0.12, p = 0.433\).
Table 3. The similar effects of MSG and NaHCO₃ supplementation on urine pH, urine electrolytes, ion exchanger gene expression and urinary metabolic markers.

|                          | Control | MSG | NaCl | NaHCO₃ |
|--------------------------|---------|-----|------|--------|
| Urine pH                 | -       | ↑   | -    | ↑      |
| Urine Electrolytes (HCO₃⁻) | -       | ↑   | -    | ↑      |
| Ion exchanger gene expression (HCO₃⁻ reabsorption, CAII, NBC1, AE1) | - | ↓ | - | ↓ |
| Urinary metabolic markers |         |     |      |        |
| Beta-hydroxyisovalerate  |         |     |      |        |
| 5-aminovalerate          |         |     |      |        |
| Glutamate                |         |     |      |        |
| Alpha-ketoglutarate      |         |     |      |        |
| Citrate                  |         |     |      |        |
| Malonate                 |         |     |      |        |
| Taurine                  |         |     |      |        |

4. Discussion

The kidney plays a dominant role in maintaining the homeostasis of plasma and urine pH by acid excretion and HCO₃⁻ reabsorption via ion exchangers. We report for the first time that short-term MSG consumption can induce alkaline urine similar to the NaHCO₃ supplementation group, and the MSG group has a similar metabolic profile with potentially similar clinical consequences.

First, we believe that the increased urinary pH in the MSG group is secondary to its glutamate composition, not to sodium itself. This is supported by the urinary pH of the NaCl group which does not increase as the amount of Na intake increased compared to the MSG group (Figure 2B). Our investigation of MSG-induced alkaline urine confirms previous data from rats receiving 20% dietary MSG for 5 weeks [29], fed 6% MSG for 3 months [30], or receiving 2 mg/g body weight MSG/day in drinking water for 9 months [14]. We also demonstrated that the MSG-treated group has similar urine electrolyte levels when compared to the NaHCO₃-treated group. MSG-treated rats have significantly higher urinary Na⁺, K⁺ and HCO₃⁻, as observed with longer supplementation [14]. The excretion of Na⁺, K⁺ and HCO₃⁻ in MSG-treated rats may suggest these elements are excessively uptaken or overproduced by metabolic pathways. Our current hypothesis is that the excess of Na⁺ derives directly from the overconsumption of MSG as shown in the NaCl group, whereas HCO₃⁻ and K⁺ derive from the catabolism of glutamate and other nutrient metabolism. The byproduct of glutamate metabolism might be similar to that of potassium citrate that generates HCO₃⁻ via its catabolic citric acid cycle, leading to the alkaline urinary pH [31]. Alkaline urine may influence the kidney’s capacity to secrete or reabsorb metabolites leading to the suppression of bicarbonate reabsorption in the kidney.

Second, the expression of ion exchangers involved in bicarbonate reabsorption in the kidney cortex of MSG-treated rats is decreased (Figure 3) and this indicates lower bicarbonate reabsorption in MSG-treated rats, similar to that of the NaHCO₃ supplemented group, which was not observed in NaCl-treated animals. The decreased NBC1 expression in the proximal tubule has been reported in rats treated with NaHCO₃ loading [32] while the immunostaining intensity of AE1 was increased in metabolic acidosis and reduced in metabolic alkalosis [33].

Third, the ¹H-NMR-based metabolomics approach revealed that the MSG-induced urinary metabolic profiles were similar to the NaHCO₃ group. In particular, MSG consumption generates a pattern of metabolites with higher levels of glutamate, alpha-ketoglutarate, malonate, citrate, beta-hydroxyisovalerate and 5-aminovalerate, whereas the level of taurine is lower than rats receiving normal drinking water, as also observed in rats receiving NaHCO₃. A quick observation of the four treatment groups showed differences in the raw spectra between 4.5 ppm and 5.25 ppm in MSG and NaHCO₃ treated rats compared to NaCl and control rats (Figure 4). In agreement with these raw
spectra, data analysis using PCA and O-PLS-DA revealed that both MSG and NaHCO$_3$ treatments show a clustering difference between treatment and control rats (Figure 5).

Ten metabolites that relate to MSG consumption are linked to catabolism of amino acids, fatty acids, vitamin, pyrimidine and citric acid cycle. For example, alpha-ketoglutarate and citrate are intermediates of the citric acid cycle. Alpha-ketoglutarate and glutamate are from transamination reactions. Beta-hydroxyisovalerate and 5-aminovaleate are leucine and lysine degradation products, respectively. Malonate is from either aspartate or fatty acid catabolism. Taurine is from cysteine or serine metabolism whereas dimethylamine and methylamine are from choline metabolism. Lastly, 5-hydroxymethyl-4-methyluracil, a marker of DNA damage, is from pyrimidine catabolism [34].

The characterization of the 10 metabolites observed in the MSG treatment group and the 11 metabolites in the NaHCO$_3$ treatment group, with some shared changes (Table 2), warrants a more detailed discussion. The higher levels of amino acid (glutamate) and amino acids-related metabolites (alpha-ketoglutarate, malonate, citrate, beta-hydroxyisovalerate and 5-aminovaleate) found in the urine of MSG and NaHCO$_3$-treated groups compared to controls may be related to their urine alkalinizing condition. Glutamate kidney re-uptake requires glutamate transporters [35], which co-transport H$^+$ with glutamate, and high urinary pH may inhibit glutamate re-uptake in the renal brush border, thus contributing to the higher urinary glutamate. Alkaline urine also inhibits metabolite reabsorption in the case of alpha-ketoglutarate, malonate and citrate in the MSG and NaHCO$_3$-treated rats. Based on their pKa, the alkaline urine may deprotonate alpha-ketoglutarate$^{1-}$, malonate$^{1-}$, and citrate$^{2-}$ to form alpha-ketoglutarate$^{2-}$, malonate$^{2-}$, and citrate$^{3-}$, respectively, and affect their reabsorption [36,37]. In metabolic/respiratory alkalosis, alpha-ketoglutarate excretion increases to levels that are several times above normal [38–40]. Under alkaline loading conditions, the blood concentration of alpha-ketoglutarate rises and net alpha-ketoglutarate reabsorption in the proximal tubule and Henle’s loop is decreased, making the alpha-ketoglutarate secretion increase in the same nephron segments, and leading to a significant increase in the urinary excretion of alpha-ketoglutarate [41,42]. Moreover, citrate, alpha-ketoglutarate, and succinate competitively inhibit the transport of each other [43].

A similar scenario is also hypothesized for malonate as citrate and malonate compete for reabsorption in the renal tubular cell [44]. The higher level of a lysine degradation product, 5-aminovaleate and leucine degradation product, beta-hydroxyisovalerate found in MSG and NaHCO$_3$-supplemented animals may relate to tissue injury. The beta-hydroxyisovalerate is itself a metabolotoxin [45]. Taurine is a normal constituent of human urine, however, its level varies markedly among individuals depending on age, hormones, stress, and diet [46], however, our control and MSG, NaHCO$_3$ groups had comparable characteristics, except for NaHCO$_3$ intake. The decrease in taurine in the MSG and NaHCO$_3$ groups may relate to either taurine use, secondary to oxidative stress, or to its degradation, as observed in chronic renal failure [47], glomerulonephritis, diabetic nephropathy, chronic renal failure, and acute kidney injury [48].

In fact, excessive renal metabolism of glutamate can be a source of ROS. Moreover, chronic MSG intake is associated with decreased levels of antioxidant enzymes and increased lipid peroxidation; leading to cellular and functional damage of the kidneys [49]. Such effects are not observed with sodium bicarbonate (NaHCO$_3$). The distinct urinary metabolites between MSG and NaHCO$_3$ are methylamine and dimethylamine, which were only observed in MSG-treated animals. Methylamine and dimethylamine are metabolites from the gut microbiota [50,51]. This gut microbiota is also found in human intestine [52]. MSG may alter the gut microbiota community, specifically those that are involved in methylamine metabolism. However, the connection of MSG consumption and methylamine metabolism needs to be further explored.

In summary, MSG consumption may resemble alkali loading (Table 3), causing suppression of ion exchangers responsible for bicarbonate absorption which correspond to the higher excretion of urinary bicarbonate in MSG and NaHCO$_3$-treated rats. MSG consumption exhibits similar features to alkaline loading, causing alkaline urine, leading to alteration of di- and tricarboxylic metabolites, i.e., glutamate,
alpha-ketoglutarate, citrate, and malonate reabsorption in the kidney. We may also speculate that MSG itself may alter the gut microbiome to catabolize dietary molecules, such as amino acids and choline and urinary metabolites could be potential markers for MSG consumption in animals and should now be studied in humans. However, there are two limitations in this present study to be aware of: the effects of MSG consumption were only tested in male animals, and the frequency of obtaining MSG was every time the animals drunk water. This behavior differs from humans because humans receiving MSG only consume MSG at their regular meal times, which is usually 2-3 times a day.

5. Conclusions

Short-term MSG consumption exhibits similar effects as consuming NaHCO$_3$, an alkalinizing agent; it induces alkaline urine and alters the ion-exchanger gene expression that relates to bicarbonate kidney reabsorption. This implies that MSG consumption induces metabolic changes with a pattern of urinary metabolites, which may be used for monitoring MSG exposure in humans.

Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/9/10/542/s1, Figure S1–S3. Changes in mRNA expression of ion exchanger genes in the cortex (left panel) and medulla (right panel) layers of rat kidney after 14 days of MSG, NaCl and NaHCO$_3$ supplementation compared to controls; Figure S4. Changes in mRNA expression of glutamate and glutamine metabolism in the cortex (left panel) and medulla (right panel) layers of rat kidney after 14 days of MSG, NaCl and NaHCO$_3$ supplementation compared to control; Figure S5. Changes in mRNA expression of TCA cycle in the cortex (left panel) and medulla (right panel) layers of rat kidney after 14 days of MSG, NaCl and NaHCO$_3$ supplementation compared to controls.

Author Contributions: Conceptualization, U.C.; Data curation, K.N., J.V.L., H.A. and U.C.; Formal analysis, K.N. and U.C.; Funding acquisition, J.V.L. and U.C.; Investigation, K.N., J.V.L., J.P. and U.C.; Methodology, K.N., J.P., C.W., R.T., A.S. and U.C.; Project administration, U.C.; Resources, J.V.L., S.A. and C.S.; Software, J.V.L.; Supervision, C.W., R.T., A.S., S.A. and C.S.; Validation, J.V.L.; Writing—original draft, K.N.; Writing—review & editing, J.V.L., C.S. and U.C.

Funding: Thanks to The Royal Golden Jubilee Ph.D. Program (RGJ-Ph.D. Program) (PHD/0124/2558) for giving the Scholarship to KN. Thanks to the Chronic Kidney Disease Northeast Thailand (CKDNET) research group (CKDNET 2561), the Invitation research fund (I56205, IN62137), the Faculty of Medicine, Khon Kaen University for the research fund to UC. JVL is funded by a MRC New Investigator Grant (MR/P002536/1) and ERC Starting Grant (715662).

Acknowledgments: We would like to thank the Northeast Laboratory Animal Center at KKU for animal husbandry facilities. Thanks to Imperial College London for technical support.

Conflicts of Interest: This study was performed in collaboration between Khon Kaen University and Imperial College London. All authors declare no other conflict of interest.

References

1. Beyreuther, K.; Biesalski, H.K.; Fernstrom, J.D.; Grimm, P.; Hammes, W.P.; Heinemann, U.; Kempski, O.; Stehle, P.; Steinhardt, H.; Walker, R. Consensus meeting: Monosodium glutamate—An update. Eur. J. Clin. Nutr. 2007, 61, 304–313. [CrossRef] [PubMed]
2. Walker, R.; Lupien, J.R. The safety evaluation of monosodium glutamate. J. Nutr. 2000, 130, 1049S–1052S. [CrossRef] [PubMed]
3. Insawang, T.; Selmi, C.; Cha’on, U.; Pethlert, S.; Yongvanit, P.; Areejitranusorn, P.; Boonsiri, P.; Khampitak, T.; Tanggrassameeprasert, R.; Pinitsoonsontorn, C.; et al. Monosodium glutamate (MSG) intake is associated with the prevalence of metabolic syndrome in a rural Thai population. Nutr. Metab. (Lond.) 2012, 9, 50. [CrossRef] [PubMed]
4. He, K.; Zhao, L.; Daviglus, M.L.; Dyer, A.R.; Van Horn, L.; Garside, D.; Zhu, L.; Guo, D.; Wu, Y.; Zhou, B.; et al. Association of monosodium glutamate intake with overweight in Chinese adults: The INTERMAP Study. Obes. (Silver Spring) 2008, 16, 1875–1880. [CrossRef] [PubMed]
5. He, K.; Du, S.; Xun, P.; Sharma, S.; Wang, H.; Zhai, F.; Popkin, B. Consumption of monosodium glutamate in relation to incidence of overweight in Chinese adults: China Health and Nutrition Survey (CHNS). Am. J. Clin. Nutr. 2011, 93, 1328–1336. [CrossRef] [PubMed]
6. Shi, Z.; Yuan, B.; Taylor, A.W.; Dai, Y.; Pan, X.; Gill, T.K.; Wittert, G.A. Monosodium glutamate is related to a higher increase in blood pressure over 5 years: Findings from the Jiangsu Nutrition Study of Chinese adults. *J. Hypertens.* 2011, 29, 846–853. [CrossRef] [PubMed]

7. Shi, Z.; Luscombe-Marsh, N.D.; Wittert, G.A.; Yuan, B.; Dai, Y.; Pan, X.; Taylor, A.W. Monosodium glutamate is not associated with obesity or a greater prevalence of weight gain over 5 years: Findings from the Jiangsu Nutrition Study of Chinese adults. *Br. J. Nutr.* 2010, 104, 457–463. [CrossRef]

8. Thu Hien, V.T.; Thi Lam, N.; Cong Khan, N.; Wakita, A.; Yamamoto, S. Monosodium glutamate is not associated with overweight in Vietnamese adults. *Public Health Nutr.* 2013, 16, 922–927. [CrossRef]

9. Ortiz, G.G.; Bitzer-Quintero, O.K.; Zarate, C.B.; Rodriguez-Reynoso, S.; Larios-Arceo, F.; Velazquez-Brizuela, I.E.; Pacheco-Moises, F.; Rosales-Corral, S.A. Monosodium glutamate-induced damage in liver and kidney: A morphological and biochemical approach. *Biomed. Pharmacother.* 2006, 60, 86–91. [CrossRef]

10. Nakanishi, Y.; Tsuneyama, K.; Fujimoto, M.; Salunga, T.L.; Nomoto, K.; An, J.L.; Takano, Y.; Iizuka, S.; Nagata, M.; Suzuki, W.; et al. Monosodium glutamate (MSG): A villain and promoter of liver inflammation and dysplasia. *J. Autoimmun.* 2008, 30, 42–50. [CrossRef]

11. Collison, K.S.; Maqbool, Z.; Saleh, S.M.; Ingls, A.; Makhoul, N.J.; Bakheet, R.; Al-Johi, M.; Al-Rabiah, R.; Zaidi, M.Z.; Al-Mohanna, F.A. Effect of dietary monosodium glutamate on trans fat-induced nonalcoholic fatty liver disease. *J. Lipid Res.* 2009, 50, 1521–1537. [CrossRef] [PubMed]

12. Nakayama, D.; Magami, Y.; Azuma, T.; Inokuchi, H.; Furukawa, M.; Ohyashiki, J.; Yoshimoto, T.; Mizuguchi, J.; Moriyasu, F.; Kawai, K.; et al. Turnover of acinar and islet cells in the pancreas of monosodium glutamate-treated obese mice. *Obes. Res.* 2003, 11, 87–94. [CrossRef] [PubMed]

13. Boonnate, P.; Waraasawapati, S.; Hipkaeo, W.; Pethlert, S.; Selmi, C.; Prasongwattana, V.; Cha’on, U. Monosodium Glutamate Dietary Consumption Decreases Pancreatic beta-Cell Mass in Adult Wistar Rats. *PLoS ONE* 2015, 10, e0131595. [CrossRef] [PubMed]

14. Sharma, A.; Prasongwattana, V.; Cha’on, U.; Selmi, C.; Hipkaeo, W.; Boonnate, P.; Pethlert, S.; Titipungul, T.; Intarawichian, P.; Waraasawapati, S.; et al. Monosodium glutamate (MSG) consumption is associated with urolithiasis and urinary tract obstruction in rats. *PLoS ONE* 2013, 8, e75546. [CrossRef] [PubMed]

15. Pak, C.Y.; Fuller, C.; Sakhaee, K.; Preminger, G.M.; Britton, F. Long-term treatment of calcium nephrolithiasis with potassium citrate. *J. Urol.* 1985, 134, 11–19. [CrossRef]

16. Mattle, D.; Hess, B. Preventive treatment of nephrolithiasis with alkali citrate—A critical review. *Urol. Res.* 2005, 33, 73–79. [CrossRef] [PubMed]

17. Mirrakhimov, A.E.; Ayach, T.; Barbaryan, A.; Talari, G.; Chadha, R.; Gray, A. The Role of Sodium Bicarbonate in the Management of Some Toxic Ingestions. *Int. J. Nephol.* 2017. [CrossRef] [PubMed]

18. Rouch, J.A.; Burton, B.; Dabb, A.; Brown, V.; Seung, A.H.; Kinsman, K.; Holdhoff, M. Comparison of enteral and parenteral methods of urine alkalinization in patients receiving high-dose metrotrexate. *J. Oncol. Pharm. Pract.* 2017, 23, 3–9. [CrossRef]

19. Adeva-Andany, M.M.; Fernandez-Fernandez, C.; Mourino-Bayolo, D.; Castro-Quintela, E.; Dominguez-Montero, A. Sodium bicarbonate therapy in patients with metabolic acidosis. *Sci. World J.* 2014, 2014, 627673. [CrossRef]

20. Browning, J.J.; Chaner, K.S. Hyperkalaemic cardiac arrhythmia caused by potassium citrate mixture. *Br. Med. J. (Clin. Res. Ed.)* 1981, 283, 1366. [CrossRef]

21. Wilson, R.G.; Farndon, J.R. Hyperkalaemic cardiac arrhythmia caused by potassium citrate mixture. *Br. Med. J. (Clin. Res. Ed.)* 1982, 284, 197–198. [CrossRef] [PubMed]

22. Choi, S.K.; Kim, Y.G.; Yoo, K.H.; Lee, D.G.; Min, G.E.; Lee, H.L. Hyperkalaemic cardiac arrhythmia resulting from short-term ingestion of potassium citrate for the management of ureter stones. *Urolithiasis* 2016, 44, 283–284. [CrossRef] [PubMed]

23. Beckonert, O.; Coen, M.; Keun, H.C.; Wang, Y.; Ebbs, T.M.; Holmes, E.; Lindon, J.C.; Nicholson, J.K. High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. *Nat. Protoc.* 2010, 5, 1019–1032. [CrossRef] [PubMed]

24. Dieterle, F.; Ross, A.; Schlotterbeck, G.; Senn, H. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. *Anal. Chem.* 2006, 78, 4281–4290. [CrossRef] [PubMed]
48. Chesney, R.W.; Han, X.; Patters, A.B. Taurine and the renal system. *J. Biomed. Sci.* **2010**, *17* (Suppl. 1), S4. [CrossRef]

49. Paul, M.V.; Abhilash, M.; Varghese, M.V.; Alex, M.; Nair, R.H. Protective effects of alpha-tocopherol against oxidative stress related to nephrotoxicity by monosodium glutamate in rats. *Toxicol. Mech. Methods* **2012**, *22*, 625–630. [CrossRef]

50. Zhu, Y.; Jameson, E.; Parslow, R.A.; Lidbury, I.; Fu, T.; Dafforn, T.R.; Schafer, H.; Chen, Y. Identification and characterization of trimethylamine N-oxide (TMAO) demethylase and TMAO permease in Methylocella silvestris BL2. *Environ. Microbiol.* **2014**, *16*, 3318–3330. [CrossRef]

51. Messenger, J.; Clark, S.; Massick, S.; Bechtel, M. A review of trimethylaminuria: (fish odor syndrome). *J. Clin. Aesthet. Dermatol.* **2013**, *6*, 45–48.

52. Rath, S.; Heidrich, B.; Pieper, D.H.; Vital, M. Uncovering the trimethylamine-producing bacteria of the human gut microbiota. *Microbiome* **2017**, *5*, 54. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).